El rendimiento de los paneles de exoma objetivo no es siempre el mismo y, en algunos casos, pueden perderse datos fundamentales para sus experimentos. Esta nota técnica interactiva proporciona datos de comparación de los paneles Exome 2.0 de Twist frente a 4 paneles disponibles en el mercado ofrecidos por otros proveedores.     

With the rapid growth and availability of next-generation sequencing has come the need for efficient target enrichment solutions across multiple applications.  Targeted sequencing maximizes testing resources by selectively narrowing sequencing output to only your regions of interest, enabling increased depth per sample and limiting cost.  As we move into the genomics era, flexible and scalable library preparation and target enrichment workflows are critical to meet the expanding diagnostic landscape. Twist continues to provide innovative NGS solutions to empower researchers; from assay development tools such as our cfDNA Pan-Cancer Reference Standards to rare variant allele detection with our Unique Molecular Identifiers (UMI).  Comprehensive identification and study of methylation biomarkers can be performed with Twist’s highly efficient methylation capture workflow.  In order to support the growing clinically relevant variants for developing NGS-based assays, Twist MRD Twist MRD Rapid 500 Panels provide researchers with customized NGS tests in as little as six business days.     In this workshop from AMP 2022, Shawn Gorda, Senior Staff Product Manager at Twist Biosciences, showcases Twist’s diverse selection of target enrichment and library preparation pipelines for NGS. He is then joined by Jonathan Keats, Assistant Professor in the Integrated Cancer Genomics Division at the Translational Genomics Research Institute (TGen), who will demonstrate how he used Twist’s UMIs and Library Preparation EF 2.0 to identify novel genetic biomarkers in multiple myeloma patients.   Solo para investigación. No diseñado para su uso en procedimientos diagnósticos.